News & Updates
Filter by Specialty:
Roflumilast shows treatment potential for seborrheic dermatitis
In the phase III STRATUM* trial, the investigational PDE4** inhibitor roflumilast improved multiple symptoms of moderate-to-severe seborrheic dermatitis (SD).
Roflumilast shows treatment potential for seborrheic dermatitis
15 Sep 2022
Low-dose methotrexate-related melanoma risk considered negligible
Individuals exposed to low-dose methotrexate risk developing melanoma, although the absolute risk increase remains very low, as shown in a recent meta-analysis.
Low-dose methotrexate-related melanoma risk considered negligible
09 Sep 2022
Topical combination, physical treatments best for mild-to-moderate acne
Topical pharmacological treatment combinations, chemical peels, and photochemical therapy are deemed to be the best and the most effective options for mild-to-moderate acne vulgaris.
Topical combination, physical treatments best for mild-to-moderate acne
06 Sep 2022
No clear link between atopic dermatitis and venous thromboembolism
There appears to be no evidence that atopic dermatitis or treatment with Janus kinase (JAK) inhibitors carries an increased risk of venous thromboembolism, according to a study.
No clear link between atopic dermatitis and venous thromboembolism
30 Aug 2022
UK Biobank: As hard water levels increase, so does the burden of eczema
Exposure to domestic hard water in high concentrations appears to go with a corresponding increase in the prevalence of eczema in adults, as reported in a UK study.
UK Biobank: As hard water levels increase, so does the burden of eczema
26 Aug 2022
OASIS-1: Thumbs up for mirikizumab in moderate-to-severe plaque psoriasis
The interleukin (IL)-23 inhibitor mirikizumab demonstrates superior efficacy in the treatment of patients with moderate-to-severe plaque psoriasis as compared with placebo, with initial responses during induction preserved through the maintenance phase, according to the results of the phase III OASIS-1 trial.
